Legal challenges to Medicare’s price negotiation initiative introduced in the Inflation Reduction Act (IRA) continue to emerge, with pharmaceutical trade organisation PhRM
Bristol-Myers Squibb has filed a lawsuit against the US government that aims to block the drug price negotiation elements of the Inflation Reduction Act (IRA), joining fel
In a new update, the US government has more than doubled the size of the latest list of medicines subject to enforced rebates if their prices rise higher than inflation.
The Centres for Medicare and Medicaid Services (CMS) has formally announced its intention to allow coverage of new amyloid-targeting drugs for Alzheimer’s disease if they
Working in the pharma industry, it’s important to be aware of the impact of policies on all stakeholders, from industry colleagues, to payers and providers, and to patients – including low-
An intriguing new study has suggested that there could be a correlation between the built environment of an area – its buildings, streets and green spaces – and the risk o